Oliver A Cornely1, Michael N Robertson2, Shariq Haider3, Andrew Grigg4, Michelle Geddes5, Mickael Aoun6, Werner J Heinz7, Issam Raad8, Urs Schanz9, Ralf G Meyer10, Sarah P Hammond11, Kathleen M Mullane12, Helmut Ostermann13, Andrew J Ullmann7, Stefan Zimmerli14, M L P S Van Iersel15, Deborah A Hepler2, Hetty Waskin2, Nicholas A Kartsonis2, Johan Maertens16. 1. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, ZKS Köln, University of Cologne, Germany, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany. 2. Merck & Co., Inc., Kenilworth, NJ, USA. 3. Juravinski Hospital & Cancer Centre, Hamilton, Ontario, Canada. 4. Austin Hospital, Heidelberg, Victoria, Australia. 5. Tom Baker Cancer Centre, Calgary, Alberta, Canada. 6. Institut Jules Bordet, Brussels, Belgium. 7. Universitätsklinikum Würzburg, Würzburg, Germany. 8. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9. Universitatsspital Zürich, Division of Hematology, University Hospital, Zürich, Switzerland. 10. St Johannes Hospital Dortmund, Dortmund, Germany. 11. Brigham & Women's Hospital, Boston, MA, USA. 12. Department of Medicine, University of Chicago, Chicago, IL, USA. 13. Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany. 14. Department of Infectious Diseases, University Hospital and Institute for Infectious Diseases, University of Bern, Bern, Switzerland. 15. NVWA, Wageningen, The Netherlands. 16. UZ Leuven Gasthuisberg Hematology, Leuven, Belgium.
Abstract
OBJECTIVES: A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as antifungal prophylaxis to neutropenic patients with AML or myelodysplastic syndrome (MDS) or to recipients at risk of invasive fungal disease (IFD) after allogeneic HSCT. METHODS: Patients (N = 237) received 300 mg of posaconazole iv twice daily on day 1, followed by 300 mg of posaconazole iv once daily for 4-28 days. After at least 5 days, patients were randomly assigned to receive posaconazole oral suspension, 400 mg twice daily or 200 mg three times daily, to complete a 28 day treatment course. Primary PK parameters were steady-state average concentration over the dosing interval (Cavg) and posaconazole trough levels (Cmin). RESULTS: Mean posaconazole Cmin was 1320 ng/mL (day 6) and 1297 ng/mL (day 8); steady-state Cmin was 1090 ng/mL (day 10). Mean steady-state posaconazole Cavg was 1500 ng/mL (day 10 or 14) and was similar in HSCT recipients (1560 ng/mL) and AML/MDS patients (1470 ng/mL). The most commonly reported treatment-related adverse events were diarrhoea (8%), nausea (5%) and rash (5%). IFD was reported in 3/237 patients (1%; 2 proven, 1 probable). CONCLUSIONS: Intravenous posaconazole at 300 mg was well tolerated, resulted in adequate steady-state systemic exposure and was associated with a low incidence of IFD in this population at high risk. TRIAL REGISTRY AND NUMBER: ClinicalTrials.gov, NCT01075984.
OBJECTIVES: A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as antifungal prophylaxis to neutropenic patients with AML or myelodysplastic syndrome (MDS) or to recipients at risk of invasive fungal disease (IFD) after allogeneic HSCT. METHODS: Patients (N = 237) received 300 mg of posaconazole iv twice daily on day 1, followed by 300 mg of posaconazole iv once daily for 4-28 days. After at least 5 days, patients were randomly assigned to receive posaconazole oral suspension, 400 mg twice daily or 200 mg three times daily, to complete a 28 day treatment course. Primary PK parameters were steady-state average concentration over the dosing interval (Cavg) and posaconazole trough levels (Cmin). RESULTS: Mean posaconazole Cmin was 1320 ng/mL (day 6) and 1297 ng/mL (day 8); steady-state Cmin was 1090 ng/mL (day 10). Mean steady-state posaconazole Cavg was 1500 ng/mL (day 10 or 14) and was similar in HSCT recipients (1560 ng/mL) and AML/MDS patients (1470 ng/mL). The most commonly reported treatment-related adverse events were diarrhoea (8%), nausea (5%) and rash (5%). IFD was reported in 3/237 patients (1%; 2 proven, 1 probable). CONCLUSIONS: Intravenous posaconazole at 300 mg was well tolerated, resulted in adequate steady-state systemic exposure and was associated with a low incidence of IFD in this population at high risk. TRIAL REGISTRY AND NUMBER: ClinicalTrials.gov, NCT01075984.
Authors: Silke Gastine; William Hope; Georg Hempel; Ruta Petraitiene; Vidmantas Petraitis; Diana Mickiene; John Bacher; Thomas J Walsh; Andreas H Groll Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: Beatrice Mercorelli; Anna Luganini; Marta Celegato; Giorgio Palù; Giorgio Gribaudo; Galina I Lepesheva; Arianna Loregian Journal: Antimicrob Agents Chemother Date: 2020-09-21 Impact factor: 5.191
Authors: Russell E Lewis; Dimitrios P Kontoyiannis; Pierluigi Viale; Eric M Sarpong Journal: Antimicrob Agents Chemother Date: 2019-09-16 Impact factor: 5.191
Authors: Beatrice Mercorelli; Marta Celegato; Anna Luganini; Giorgio Gribaudo; Galina I Lepesheva; Arianna Loregian Journal: Antiviral Res Date: 2021-03-13 Impact factor: 5.970
Authors: Arathi A Lambrix; Hope D Swanson; Jennifer L Pauley; Allison W Bragg; Delia C Carias; Melissa S Bourque; Yinmei Zhou; Cheng Cheng; William L Greene; Gabriela Maron Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790
Authors: Jannik Stemler; Philipp Koehler; Christian Maurer; Carsten Müller; Oliver A Cornely Journal: Ann Hematol Date: 2020-06-08 Impact factor: 3.673